Skip to content

CninMed – China Innovative Drugs Update

  • Contact Us
Posted in
  • China License Out

[China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D/BCMA/CD3 TsAbs SIM0500

Announced Date: 2025-01-13 (January 13, 2025) Asset Name: SIM0500 Licensor: Simcere Zaiming (a subsidiary of Simcere … [China BD 2025] Simcere Zaiming and AbbVie enters a 1 billion license on CFBi GPRC5D/BCMA/CD3 TsAbs SIM0500Read more

by admin•January 14, 2025September 1, 2025•0
Posted in
  • China License Out

[China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a  preclinical small molecule asset

Announced Date: 2025-01-10 (January 10, 2025) Asset Name: Undisclosed Licensor: InSilico Medicine (China) Licensee (Buyer): Stemline … [China BD 2025] Insilico Medicine and Menarini (Stemline) enters a 570 million USD license on a  preclinical small molecule assetRead more

by admin•January 11, 2025September 7, 2025•0
Posted in
  • China License Out

[China BD 2025] Sciwind Biosciences and Verdiva Bio enters 2.47 Billion USD License on Three Metabolic Diseases Product Candidates

Announced Date: 2025-01-10 ( January 10, 2025) Licensor (Seller): Sciwind Biosciences (China) Licensee (Buyer):  Verdiva Bio (US) … [China BD 2025] Sciwind Biosciences and Verdiva Bio enters 2.47 Billion USD License on Three Metabolic Diseases Product CandidatesRead more

by admin•January 10, 2025October 16, 2025•0
Posted in
  • China License Out

[China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR/HER3 BsADC DB-1418 (AVZO-1418)

Announced Date: 2025-01-07 (January 7, 2025) Asset Name: DB-1418 (AVZO-1418) Licensor (Seller): Duality Biotherapeutics (China) Licensee (Buyer): … [China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR/HER3 BsADC DB-1418 (AVZO-1418)Read more

by admin•January 8, 2025September 8, 2025•0
Posted in
  • China License Out

[China BD 2025] Innovent and Roche enters a 1 billion USD license on DLL3 ADC IBI3009

Announced Date: 2025-01-02 (January 2, 2025) Asset Name: IBI3009 Licensor: Innovent (Innovent Biologics, Inc.，China) Licensee (Buyer): … [China BD 2025] Innovent and Roche enters a 1 billion USD license on DLL3 ADC IBI3009Read more

by admin•January 3, 2025September 1, 2025•0
Posted in
  • China License Out

[China BD 2024] Jemincare and RAPT Therapeutics Enters a 708 million USD License for anti-IgE Monoclonal Antibody JYB1904 (RPT904)

Announced Date: 2024-12-23 (December 23, 2024) Asset Name: JYB1904 (RPT904) Licensor (Seller): Shanghai Jemincare Pharmaceutical (China) … [China BD 2024] Jemincare and RAPT Therapeutics Enters a 708 million USD License for anti-IgE Monoclonal Antibody JYB1904 (RPT904)Read more

by admin•December 24, 2024October 21, 2025•0
Posted in
  • China License Out

[China BD deal 2024]Hansoh and MSD enters a 2 billion USD license on GLP-1Ra HS-10535

Announced Date: 2024-12-18 (December 18, 2024) Asset Name: HS-10535 Licensor: Hansoh Pharma  (China) Licensee (Buyer):  MSD … [China BD deal 2024]Hansoh and MSD enters a 2 billion USD license on GLP-1Ra HS-10535Read more

by admin•December 19, 2024September 1, 2025•0
Posted in
  • China License Out

[China BD 2024] VelaVigo and Avenzo Enters a 800 million USD License on Nectin4/TROP2 BsADC Program

Announced Date: 2024-11-18 (November 18, 2024) Asset Name: Licensor: VelaVigo Bio (China) Licensee (Buyer): Avenzo Therapeutics … [China BD 2024] VelaVigo and Avenzo Enters a 800 million USD License on Nectin4/TROP2 BsADC ProgramRead more

by admin•November 19, 2024September 3, 2025•0
Posted in
  • China License Out

[China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1/VEGF BsAbs LM-299

Announced Date: 2024-11-14 (November 14, 2024) Asset Name: LM-299 Licensor: LaNova Medicines Ltd. (LaNova) (China) Licensee … [China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1/VEGF BsAbs LM-299Read more

by admin•November 15, 2024September 9, 2025•0
Posted in
  • China Biotech M&A
  • China License Out

[China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)

Announced Date: 2024-11-13 (November 13, 2024) Licensor (Seller): Zhuhai Biotheus Inc (China) Licensee (Buyer): BioNTech . … [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)Read more

by admin•November 14, 2024September 18, 2025•1

Posts pagination

Previous 1 … 4 5 6 … 10 Next

Recent Posts

  • [China BD 2025] TransThera and Neurocrine Enters a 882 USD Million License on NLRP3 Inhibitor Program
  • China NMPA Approved New Drugs (Biological Products) ADC
  • [China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105
  • [China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031N
  • [China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on  Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)

Recent Comments

  1. [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327) – CninMed – China Innovative Drugs Update on [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  2. [Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products – CninMed – China Innovative Drugs Update on [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
  3. [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus) – CninMed – China Innovative Drugs Update on [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  4. admin on [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Categories

  • China Biotech M&A
  • China FIC Drug
  • China License Out
  • China New Drug
  • China NewCo
  • China Original Asset
  • China Tech Corp
Copyright © 2025 CninMed - China Innovative Drugs Update.
Powered by WordPress and HybridMag.
  • Contact Us